After Combining Assets, Takeda/Millennium Outline Oncology Strategy

With 13 oncology molecules in the clinic, R&D priorities include motesanib for lung cancer, an aurora A kinase inhibitor and expansion of Takeda’s prostate cancer expertise.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet